4-chlorobenzyl (1S,3R)-1-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide | 515157-14-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 4-chlorobenzyl (1S,3R)-1-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-beta-carboline-3-carboxamide
• 英文别名: (1S,3R)-N-[(4-chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide
• CAS: 515157-14-9
• 化学式: C₂₅H₂₀Cl₃N₃O
• 分子量: 484.812
• InChiKey: JQVYGRHHEWFKNA-PKTZIBPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  56.9
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：PTC Therapeutics, Inc.

  公开号：EP3718405A1

  公开（公告）日：2020-10-07

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replications or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one ore more additional therapies to a human in need of such treatment.

  描述了选择性抑制人类血管内皮生长因子（VEGF）病理性生成的化合物以及包含此类化合物的组合物。描述了抑制病毒复制或病毒 RNA 或 DNA 或病毒蛋白产生的化合物以及包含此类化合物的组合物。还描述了使用此类化合物减少血管内皮生长因子的方法，以及涉及施用此类化合物的治疗癌症和非肿瘤性疾病的方法。还描述了使用此类化合物抑制病毒复制或病毒 RNA 或 DNA 或病毒蛋白产生的方法，以及施用此类化合物治疗病毒感染的方法。这些化合物可作为单剂疗法或与一种或多种额外疗法结合施用给需要治疗的人。
• Heteroaryl - fused nitrogen heterocycles as therapeutic agents
  申请人：Mjalli M. M. Adnan

  公开号：US20050096335A1

  公开（公告）日：2005-05-05

  This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.

  本发明提供了可用作蛋白酪氨酸磷酸酶（PTPase）抑制剂的化合物。作为 PTP 酶的抑制剂，本发明的化合物可用于管理、治疗、控制和辅助治疗由 PTP 酶活性介导的疾病。这些疾病包括 I 型糖尿病、II 型糖尿病、免疫功能障碍、艾滋病、自身免疫、葡萄糖不耐受症、肥胖症、癌症、牛皮癣、过敏性疾病、传染性疾病、炎症性疾病、涉及生长激素合成调节或影响生长激素产生的生长因子或细胞因子合成调节的疾病或阿尔茨海默病。
• BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS
  申请人：TransTech Pharma Inc.

  公开号：EP1438310B1

  公开（公告）日：2006-12-20
• METHODS FOR TREATING NEUROFIBROMATOSIS
  申请人：Cao Liangxian

  公开号：US20120157401A1

  公开（公告）日：2012-06-21

  Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
• US9351964B2
  申请人：——

  公开号：US9351964B2

  公开（公告）日：2016-05-31